The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas - refine.bio

GSE47864

Homo sapiens

16 Downloadable Samples

Technology Badge Icon

Affymetrix Human Gene 1.0 ST Array (hugene10st)

Submitter Supplied Information

Description

Rigosertib treatment of head and neck squamous cell cancer

PubMed ID

Publication Title

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Total Samples

16

Submitter’s Institution

University of Colorado Anschutz Medical Campus

Authors

Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, Aisner DL, Wilhelm F, Frederick BA, Varella-Garcia M, Tan AC, Jimeno A

Source Repository

Gene Expression Omnibus (GEO)

No rows found

Loading...